Digital Partnering | September 16–17, 2025
10 Sept - Asia Bio Day 2 (Agenda is subject to change) - SGT / Singapore
APAC is redefining the global biotech landscape, driven by innovation, investment, and evolving regulations. This dynamic panel unites global leaders to explore how the region can navigate geopolitical shifts, scale breakthroughs, and lead in next-generation therapeutics. With a focus on international collaboration, the discussion will uncover strategies to tackle shared challenges and unlock opportunities for global biotech growth.
- How are global geopolitical and economic dynamics shaping the future of biotech in APAC and beyond?
- What are some of the investment patterns driving biotech growth across the region, and how do they compare to those in North America, Europe, and other emerging markets?
- Can APAC take the lead in developing cutting-edge biotech technologies, and how can global cooperation ensure equitable access to these advancements?
Session Themes: Strategy / Collaboration / Investment / Innovation / Global Expansion
Across Asia, NewCos are emerging as a powerful tool for biotech innovation, unlocking capital, enabling focused execution, and driving cross-border dealmaking. Whether through spin-outs, asset-centric models, or joint ventures, NewCos are reshaping how companies scale and go global. This esteemed panel explores the evolving art of the deal: what’s working, what’s next, and how pharma, VCs, and startups are collaborating to build the next generation of biotech success stories.
- What are NewCos and how are biotechs using them to de-risk R&D, accelerate speed to market, and pursue global ambitions?
- What deal structures (M&A, licensing, spin-outs, JVs) are defining the next wave of biotech growth in Asia?
- How do you balance strategic control, scientific focus, and capital efficiency in today’s deals?
- Trends in pharma-Biotech and VC-Biotech partnerships that are shaping Asia’s role in the global ecosystem.
Session Themes: Investment Trends / Dealmaking / Strategic Partnerships
As APAC emerges as a leader in next-generation therapies such as live biotherapeutics and cell & gene therapies. However, it faces challenges in regulatory alignment, infrastructure, and partnership models. This session explores how biotech companies and regional stakeholders can align strategies to bring these therapies to market faster and more effectively. Panelists will also discuss overcoming regulatory fragmentation, addressing manufacturing bottlenecks, and the strategic value of cross-border and public-private partnerships.
- How feasible is regulatory harmonization for novel therapeutics in APAC, and who should drive it?
- What infrastructure is critical to support manufacturing and clinical development for emerging therapies?
- What types of partnerships (cross-border, Public Private Partnership, academic) are proving most impactful in bringing these therapies to patients?
Session Themes: Regulatory Strategy / Strategic Partnerships / Infrastructure
In an uncertain funding climate, biotech companies must refine their business case and narrative to attract investment. This session brings together investors and seasoned executives to discuss how capital is flowing across the region, what sets a pitch apart, and how to how to thrive in an increasingly competitive environment.
- What do today’s investors really want from biotech CEOs in APAC?
- How can early-stage companies stand out in a crowded, capital-constrained market?
- What role do platform technologies, delivery innovations, and team credibility play in funding decisions?
- How are funding priorities evolving both regionally and globally, and what trends should founders watch for?
Session Themes: Strategy / Investment / Dealmaking / Capital Markets
As Asia solidifies its place in the global biotech ecosystem, the region is becoming a hotbed for cross-border M&A, licensing, and strategic partnerships. But behind every headline-making deal lies a complex interplay of cultural nuance, market dynamics, and talent dynamics. In this dynamic closing panel, biotech, pharma, and investment leaders will share how to navigate the art and science of dealmaking in Asia, from trust-building and negotiation styles to talent alignment, valuation trends, and long-term value creation. Expect a candid, high-energy conversation full of practical insight and deal-tested wisdom.
- How do cultural dynamics influence deal structures and timelines in key APAC markets?
- What makes a biotech company in Asia an attractive partner or acquisition target for global players—and vice versa?
- Are valuations in APAC catching up with global markets, or does a gap persist?
- How can companies overcome regulatory, operational, cultural, and talent-related challenges when executing and integrating cross-border deals?
Session Themes: Dealmaking / Strategic Partnerships / Cultural Intelligence / Global Strategy
The state-owned trade and investment Agency NRW.Global Business is the partner for all companies when it comes to investment projects and settling in North Rhine-Westphalia, Germany's No. 1 investment location. NRW.Global Business furthermore conducts activities to support companies from NRW in international growth markets and in networking with international business partners. In close coordination with its partners, NRW.Global Business provides a variety of measures tailored to the companies' needs: It is responsible for the organisation of joint trade fair presentations abroad as well as the coordination and support of international trade delegations from North Rhine-Westphalia to foreign countries. Numerous other industry information and brokerage events offer companies additional assistance in setting up and expanding international business.
- Yazmin Stoffer - Head of Business Unit ASEAN, NRW.Global Business GmbH
CK Life Sciences, a member of the CK Hutchison Group, is listed on the Hong Kong Stock Exchange. With an ambition of improving Health & Wellness, CK Life Sciences is engaged in healthcare R&D, with operating businesses in Nutraceuticals and Agricultural-related sectors providing steady revenue that enables our R&D sustainability.
CaSRevolution is a biotech company developing a first-in-class therapeutic approach for Alzheimer’s disease. Our innovation targets the Calcium Sensing Receptor (CaSR), a key trigger of the neurotoxic cascade initiated by Abeta oligomers. By blocking CaSR with proprietary Negative Allosteric Modulators, we aim to halt amyloid accumulation, tau hyperphosphorylation, and neuroinflammation, addressing Alzheimer’s at its root cause.
DotBio is an emerging biotech company based in Singapore and San Francisco, focused on the rapid development of next-generation antibody therapeutics for diseases with significant unmet need. DotBio’s platform integrates advances in computational biology and molecular engineering to efficiently generate high-quality antibodies against challenging targets, including both extracellular and intracellular targets involved in cancer and autoimmune disorders.
Nanjing Chia-Tai Tianqing Pharmaceutical Company (NJCTTQ), was jointly founded by CP Group, a Thai company and Jiangsu Nongken Group. NJCTTQ specializes in research and development, production and commercialization of drugs for cardiovascular diseases, tumors, tumors supportive care, perioperative care, gastrointestinal disorders and contrast agents. We have more than 10 innovative programs, covering areas such as breast cancer, IgAN, PNH, acromegaly and etc for out-licensing. We also welcome opportunities for in-licensing projects. We embrace various models of cooperation
TaiMed Biologics is a publicly listed biotechnology company headquartered in Taipei, Taiwan, dedicated to developing and commercializing innovative biologics that address urgent unmet medical needs. Founded in 2007, TaiMed has built a global reputation as a pioneer in HIV monoclonal antibody therapeutics, with proven capabilities spanning discovery, clinical development, regulatory approval, and large-scale biologics manufacturing.
Matwings, founded in 2021 by an elite team from Shanghai Jiao Tong University,is one of China's pioneering enterprises in AI-driven protein function prediction and design. The company is dedicated to combining AI technology to provide end-to-end,full-process solutions from protein design, lab validation,and pilot trial to intermediate and commercial-scale production. Matwings independently developed AIACCLBIOTM model, a universal AI platform for protein function prediction, originating from the Venus models developed by Professor Hong Liang’s team at SJTU. This innovation establishes a new paradigm-enabled automated design combined with minimal experimental validation to directly predict protein function instead of via the structure-based model, thus effectively addressing challenges that rely on "expert experience & extensive trial-and-error," including long experimental development, high costs, low positive rates, and difficulties in multi-objective optimization.AIACCLBIOTM significantly enhances protein performance, shortens R&D cycles, reduces development costs, and supports clients in building high-barrier patent portfolios. In just over three years, Matwings has delivered more than 30 protein design projects, highly credited from clients, and established long-term strategic partnerships. Currently, the company's technical services have expanded into multiple downstream fields. The company has been awarded with,including but not limited to,National High-Tech Enterprise,"Specialized, Fine, Special,and New" Small and Medium-sized Enterprise in Shanghai,the "Emerging Enterprise" award for technology entrepreneurship in Minhang District in Shanghai.Matwings has completed three rounds of financing,with investments from star VCs such as Qiming Venture Partners,3E Bioventures Capital, and GSR United Capital.